Loading...
•
Sep 30, 2021
Scorpius Holdings Q3 2021 Earnings Report
Heat Biologics reported a net loss and provided a business update for Q3 2021.
Key Takeaways
Heat Biologics reported a net loss attributable to the company of $7.4 million, or ($0.30) per basic and diluted share, for the quarter ended September 30, 2021. The company had approximately $108.9 million in cash, cash equivalents and short investments as of September 30, 2021.
Recognized $0.5 million of grant revenue for qualified expenditures under the CPRIT grant.
Research and development expense was $4.4 million.
General and administrative expense was $3.4 million, primarily due to a decrease in stock-based compensation expense.
Expanded dosing in Phase 1 clinical trial of monoclonal antibody PTX-35 in patients with solid tumors.